AstraZeneca has published a study of more than a million people vaccinated against COVID-19: it reduced hospitalizations by 94% and was found to be effective in the elderly

AstraZeneca reported on Monday the publication of preliminary results a study by the Scottish Public Health Service which estimates the effectiveness of the first doses of vaccination against COVID-19, obtained after immunizing 1,137,775 people (35% of the population) over the age of 18, most of them adults over 65.

According to this study in real conditions, the AstraZeneca vaccine Reduces COVID-19 hospitalization by 94% within 28-34 days of vaccination. Likewise, when analyzing the combined efficacy of different vaccines, similar results in all age groups, including those 80 and over.

These data provide additional evidence that reinforces the results obtained in the combined analysis of clinical trials conducted in the UK, Brazil and South Africa in which there were no cases of hospitalization or serious illness due to COVID-19 after 22 days of administration. AstraZeneca vaccine.

“This study proposes Encouraging data on the impact of vaccination against the COVID-19 pandemic. This is the first data that suggests a significant reduction in hospitalizations and serious illness from COVID-19 and brings us closer to the common goal: to prevent COVID-19 from continuing to threaten the lives of people around the world. At AstraZeneca, we will continue to work to put our science, innovation and corporate strength at the disposal of society to end this pandemic, ”commented AstraZeneca Spain Medical Director Ana Pérez.

The vaccine’s effectiveness was 59.5 percent for symptomatic cases in participants who received the two recommended doses with a dose interval of 4 to 12 weeks. The results of a combined analysis of Phase II / III clinical trials in the United Kingdom, Brazil and South Africa published on February 19 in The Lancet show that after the first dose, a 76% vaccine effectiveness maintaining protection until the second dose.

The Efficacy after the second dose increases up to 82 percent when the second dose is given with an interval between doses of 12 weeks or more.

The Strategic Advisory Group of Experts (SAGE) of the World Health Organization (WHO), in charge of the study of the vaccine, also ensured that the vaccine was effective against the British strain.

(With information from Europa Press)

MORE ON THIS TOPIC: